A Randomized Double-blind Controlled Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia Patients.
试验速览
- 阶段
- 不适用
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Change from baseline in clinical improvement of negative symptoms (Scale for Assessment of Negative Symptoms [SANS], and Positive and Negative Syndrome Scale [PANSS] negative symptoms subscale)
研究概览
简要总结
This study is to determine whether high frequency repetitive transcranial magnetic stimulation (rTMS) is effective in the treatment of negative symptoms in schizophrenia patients
详细描述
The principal objective of this trial is to investigate the effect of high frequency rTMS on negative symptoms in schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 15 Years 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The diagnosis of schizophrenia according to DSM-IV；
- •18～55 years old；
- •schizophrenic illness duration longer than one year;
- •The sum of negative scores in the range Positive and negative symptom score (PANSS) must be 20 points or higher, at least one item from the area of negative symptoms (N1-N7) must be ≥ 4 points (at least moderate, clinically significant symptoms), and improvement in negative symptom-sum (measuring by PANSS) must be 10% or lower during the last two weeks before rTMS stimulation.
- •Have a stable and consistent drug treatment at least two weeks prior the rTMS treatment;
- •Able to adhere to the treatment schedule;
- •Dextromanual, normal vision and hearing;
- •Signed an informed consent
排除标准
- •rTMS contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure;
- •Acute risk of suicide and impulse；
- •patients to be diagnosed according to DSM-IV for substance abused, development delayed;
- •suffering from serious physical disease and can not accept the treatment;
- •history of epileptic seizures or the presence of epileptic activity documented on the basis of EEG;
- •difficult to maintain the current drug treatment for at least 1 month;
- •undergoing ECT or MECT in last 3 months;
- •current treatment with anticonvulsant acting drugs such as anticonvulsants, benzodiazepines.
研究组 & 干预措施
Active rTMS
Active treatment will be delivered at an intensity that is 120% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 50 stimuli each (i.e., 3000 stimuli) and an intertrain interval of 10 sec. Treatment will be applied in sequential order to the dorsomedial prefrontal cortices (DMPFC).
干预措施: Repetitive Transcranial Magnetic Stimulation (Device)
Sham rTMS
Sham stimulation will be delivered using the same stimulation parameters and at the same site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
干预措施: Repetitive Transcranial Magnetic Stimulation (Device)
结局指标
主要结局
Change from baseline in clinical improvement of negative symptoms (Scale for Assessment of Negative Symptoms [SANS], and Positive and Negative Syndrome Scale [PANSS] negative symptoms subscale)
时间窗: 3 times (Before treatment,immediately after treatment,4 weeks after treatment)
次要结局
- Change from baseline in WHO Disability Assessment Schedule 2.0 [WHODAS 2.0](3 times (Before treatment,immediately after treatment,4 weeks after treatment))
- Change from baseline in clinical global impression [CGI](3 times (Before treatment,immediately after treatment,4 weeks after treatment))
- Change from baseline in Simpson-Angus Scale [SAS](3 times (Before treatment,immediately after treatment,4 weeks after treatment))
- Change from baseline in Positive and Negative Syndrome Scale [PANSS] positive symptoms subscale(3 times (Before treatment,immediately after treatment,4 weeks after treatment))
- Change from baseline in Calgary Depression Scale for Schizophrenia [CDSS](3 times (Before treatment,immediately after treatment,4 weeks after treatment))
- Change from baseline in Clinician Rated Dimensions of Psychosis Symptom [CRDPS](3 times (Before treatment,immediately after treatment,4 weeks after treatment))